Aminopterin dosage forms
AssigneeAminopterin LLC
InventorJohn A. Zebala
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
Claims24
A method for treating an inflammatory disorder in a patient, comprising administering to said patient, in uninterrupted cycles, a pharmaceutical composition comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of aminopterin comprises a weekly dosage of 0.005 to 0.03 mg aminopterin, disodium salt per kg body weight, and wherein the inflammatory disorder is selected from the group consisting of bronchopulmonary dysplasia, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, inflammatory bowel disease, and canine atopic dermatitis.
A method for treating an inflammatory disorder in a patient, comprising administering to said patient, in uninterrupted cycles, a pharmaceutical composition comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of aminopterin is a dosage of 0.03 mg/m2 to 2 mg/m2 aminopterin, disodium salt, and wherein the inflammatory disorder is selected from the group consisting of bronchopulmonary dysplasia, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, inflammatory bowel disease, and canine atopic dermatitis.
Dependencies are inferred from the claim text.